Figure 4.
Overall survival in patients stratified by HLC ratio. Median survival was 40.5 months in patients with highly abnormal HLC ratio (red line) and was not reached in those with less abnormal HLC ratio (blue line, P=0.016) (a). Patients achieving a PR or better were assessed at best response (b). In this group, patients with a normal HLC ratio (blue line) had a significantly longer survival from maximum response (P=0.04) compared with those with an abnormal HLC ratio (red line). Similarly, patients achieving a VGPR or better were compared (c). Patients with a normal HLC ratio (blue line) had a tendency for longer overall survival compared with those with an abnormal HLC ratio (red line) although significance was not reached.